Disease Clusters?

Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.

← Back to all clusters

Cluster 3

45 diseases · 93 shared-gene connections
45 Diseases
393 Unique genes
0.167 Avg. similarity score
Adrenocortical carcinoma Most-connected disease (14 links)
Log in to save this analysis

Save This Analysis

Disease Searched: snijders blok-campeau syndrome Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details · click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) · drag a node to pin it in place · scroll/pinch to zoom.

Member diseases (most connected first ‐ the cluster's core)

Disease ⇵ Connections in cluster ⇵ Significant partners ⇵ Curated genes ⇵
Adrenocortical carcinoma 14 14 1
Choroid plexus carcinoma 14 14 1
Choroid plexus papilloma 12 12 1
Bone osteosarcoma 8 8 3
B-lymphoblastic leukemia/lymphoma 7 7 19
Bone marrow failure syndromes 7 7 9
Li-fraumeni syndrome 7 7 5
Sezary syndrome 7 7 27
Vulvar lichen sclerosus 7 7 2
Endometrial hyperplasia 6 6 10
Hemangiosarcoma 6 6 18
Small cell carcinoma 6 6 9
Urogenital neoplasms 6 6 5
Urologic neoplasms 6 6 8
Demyelinating diseases 5 5 11
B-cell chronic lymphocytic leukemia 4 4 8
Breast implant-associated anaplastic large cell lymphoma 4 4 6
Carcinogenesis 4 4 18
Nasopharyngeal carcinoma 4 4 22
Sapho syndrome 4 4 5
B-cell acute lymphoblastic leukemia 3 3 60
CHEK2-related cancer predisposition 3 3 1
Central nervous system neoplasms 3 3 2
Chromosome 17 deletion 3 3 2
Congenital bone marrow failure syndrome 3 3 3
Osteogenic sarcoma 3 3 2
Osteosarcoma 3 3 57
Retinoblastoma 3 3 1
Aplasia and myelodysplasia 2 2 1
Growth hormone insensitivity syndrome with immune dysregulation 2 2 2
Lymphoblastic leukemia 2 2 57
Merkel cell carcinoma 2 2 1
Small cell lung carcinoma 2 2 91
Uterine neoplasms 2 2 38
immune dysregulation, autoimmunity, and autoinflammation 2 2 1
Autoinflammation, immune dysregulation, and eosinophilia 1 1 1
Cervicitis 1 1 1
Congenital progressive bone marrow failure-b-cell immunodeficiency-skeletal dysplasia syndrome 1 1 1
Familial telangiectasia cancer syndrome 1 1 1
Gestational trophoblastic disease 1 1 1
Nasopalpebral lipoma-coloboma syndrome 1 1 1
Uinary system neoplasms 1 1 2
granulocytopenia with immunoglobulin abnormality 1 1 1
leukemia, acute myeloid, susceptibility to 1 1 1
snijders blok-campeau syndrome 1 1 1

Top shared genes (genes linked to 2+ member diseases)

Gene ⇵ Member diseases ⇵ Linked diseases
TP53 23 / 45 Adrenocortical carcinoma, B-cell chronic lymphocytic leukemia, B-lymphoblastic leukemia/lymphoma, Bone marrow failure syndromes and 19 more
CDKN2A 9 / 45 B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma, Carcinogenesis, Endometrial hyperplasia and 5 more
RB1 7 / 45 Bone osteosarcoma, Osteogenic sarcoma, Osteosarcoma, Retinoblastoma and 3 more
CCND1 5 / 45 B-cell chronic lymphocytic leukemia, Hemangiosarcoma, Nasopharyngeal carcinoma, Urologic neoplasms and 1 more
CHEK2 5 / 45 Bone osteosarcoma, CHEK2-related cancer predisposition, Li-fraumeni syndrome, Osteogenic sarcoma and 1 more
KRAS 5 / 45 Carcinogenesis, Endometrial hyperplasia, Hemangiosarcoma, Nasopharyngeal carcinoma and 1 more
MYC 5 / 45 Demyelinating diseases, Hemangiosarcoma, Merkel cell carcinoma, Osteosarcoma and 1 more
FLT3 4 / 45 B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma, leukemia, acute myeloid, susceptibility to, Lymphoblastic leukemia
PTEN 4 / 45 Endometrial hyperplasia, Nasopharyngeal carcinoma, Sezary syndrome, Small cell lung carcinoma
VEGFA 4 / 45 Hemangiosarcoma, Osteosarcoma, Urologic neoplasms, Uterine neoplasms
BAP1 3 / 45 Central nervous system neoplasms, Nasopharyngeal carcinoma, Uterine neoplasms
CSF3 3 / 45 Hemangiosarcoma, Small cell lung carcinoma, Uterine neoplasms
CTNNB1 3 / 45 Endometrial hyperplasia, Hemangiosarcoma, Uterine neoplasms
EGFR 3 / 45 Osteosarcoma, Small cell lung carcinoma, Uterine neoplasms
ERCC6L2 3 / 45 Bone marrow failure syndromes, Congenital bone marrow failure syndrome, Growth hormone insensitivity syndrome with immune dysregulation
GATA3 3 / 45 B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma, Carcinogenesis
IKZF1 3 / 45 B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma, Lymphoblastic leukemia
PIP4K2A 3 / 45 B-cell acute lymphoblastic leukemia, B-lymphoblastic leukemia/lymphoma, Lymphoblastic leukemia
PLCG1 3 / 45 Hemangiosarcoma, immune dysregulation, autoimmunity, and autoinflammation, Sezary syndrome
SMARCA4 3 / 45 Sezary syndrome, Small cell carcinoma, Small cell lung carcinoma
SRP72 3 / 45 Aplasia and myelodysplasia, Bone marrow failure syndromes, Congenital bone marrow failure syndrome
ABL1 2 / 45 B-lymphoblastic leukemia/lymphoma, Carcinogenesis
ARID1A 2 / 45 Nasopharyngeal carcinoma, Sezary syndrome
ARID5B 2 / 45 B-cell acute lymphoblastic leukemia, Lymphoblastic leukemia
ATR 2 / 45 Familial telangiectasia cancer syndrome, Urologic neoplasms
BCR 2 / 45 B-lymphoblastic leukemia/lymphoma, Lymphoblastic leukemia
BIRC5 2 / 45 Small cell carcinoma, Uterine neoplasms
BRAF 2 / 45 Carcinogenesis, Sezary syndrome
BRCA2 2 / 45 Breast implant-associated anaplastic large cell lymphoma, Small cell lung carcinoma
CDKN1B 2 / 45 Sezary syndrome, Uterine neoplasms
CEBPE 2 / 45 B-cell acute lymphoblastic leukemia, Lymphoblastic leukemia
CHD3 2 / 45 Sezary syndrome, snijders blok-campeau syndrome
CREBBP 2 / 45 Sezary syndrome, Small cell lung carcinoma
CSF2 2 / 45 B-cell acute lymphoblastic leukemia, Bone marrow failure syndromes
DNAJC21 2 / 45 Bone marrow failure syndromes, Congenital bone marrow failure syndrome
ERBB2 2 / 45 Carcinogenesis, Nasopharyngeal carcinoma
ERCC1 2 / 45 Nasopharyngeal carcinoma, Uterine neoplasms
GSDMB 2 / 45 B-cell acute lymphoblastic leukemia, Lymphoblastic leukemia
HYOU1 2 / 45 B-cell acute lymphoblastic leukemia, granulocytopenia with immunoglobulin abnormality
IKZF3 2 / 45 B-cell acute lymphoblastic leukemia, B-cell chronic lymphocytic leukemia
IL32 2 / 45 Cervicitis, Sezary syndrome
JAK1 2 / 45 Autoinflammation, immune dysregulation, and eosinophilia, Breast implant-associated anaplastic large cell lymphoma
JAK2 2 / 45 Breast implant-associated anaplastic large cell lymphoma, Uterine neoplasms
JUN 2 / 45 Hemangiosarcoma, Osteosarcoma
KMT2A 2 / 45 B-lymphoblastic leukemia/lymphoma, Small cell lung carcinoma
LHPP 2 / 45 B-cell acute lymphoblastic leukemia, Lymphoblastic leukemia
MDM2 2 / 45 Li-fraumeni syndrome, Sapho syndrome
MET 2 / 45 Carcinogenesis, Osteosarcoma
MMP2 2 / 45 Nasopharyngeal carcinoma, Osteosarcoma
MST1R 2 / 45 Nasopharyngeal carcinoma, Osteosarcoma
MTOR 2 / 45 Small cell carcinoma, Uterine neoplasms
MYSM1 2 / 45 Bone marrow failure syndromes, Congenital progressive bone marrow failure-b-cell immunodeficiency-skeletal dysplasia syndrome
PAX5 2 / 45 B-lymphoblastic leukemia/lymphoma, Lymphoblastic leukemia
POU5F1 2 / 45 Carcinogenesis, Gestational trophoblastic disease
SIRT1 2 / 45 Demyelinating diseases, Osteosarcoma
SLC2A13 2 / 45 Uinary system neoplasms, Urogenital neoplasms
SOX2 2 / 45 Osteosarcoma, Small cell lung carcinoma
STAT3 2 / 45 Breast implant-associated anaplastic large cell lymphoma, Uterine neoplasms
SULT1A1 2 / 45 B-cell acute lymphoblastic leukemia, Urologic neoplasms
TMEM132D 2 / 45 B-cell acute lymphoblastic leukemia, Small cell lung carcinoma
TP63 2 / 45 Lymphoblastic leukemia, Nasopharyngeal carcinoma
WDR11 2 / 45 Uinary system neoplasms, Urogenital neoplasms
ZDBF2 2 / 45 Nasopalpebral lipoma-coloboma syndrome, Small cell lung carcinoma
What do these columns mean?
Connections in cluster
How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
Significant partners
How many of those links are statistically significant (FDR q < 0.05).
Curated genes
Distinct curated genes linked to that disease in GeDiPNet.
Member diseases (Top shared genes)
How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
Overlap genes (x / y)
x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
Cluster gene count
Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
Fold enrichment
Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
P-value / FDR q-value
Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
Shared genes (Pairs within this cluster)
Number of curated genes the two diseases in that row have in common.
Similarity score (Pairs within this cluster)
Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.

Enriched Pathways (why this cluster is grouped, biologically)

Pathway ⇵ Source ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
Pathways in cancer
TP53, APC, CDKN2A, CTNNB1, KRAS, PTEN, JAK1, BAK1, CEBPA, FLT3, IL7, NFKB1
 KEGG 70 / 533 4.0× 3.04e-24 4.77e-21 ✓ sig.
Prostate cancer
TP53, CTNNB1, KRAS, PTEN, ERG, NFKB1, CCND1, PDGFRA, RB1, AKT1, BRAF, ERBB2
 KEGG 27 / 98 8.4× 3.99e-18 2.29e-15 ✓ sig.
Breast cancer
TP53, APC, CTNNB1, KRAS, PTEN, BAK1, CCND1, RB1, BRCA1, BRCA2, AKT1, BRAF
 KEGG 31 / 148 6.4× 6.75e-17 3.04e-14 ✓ sig.
Chronic myeloid leukemia
TP53, CDKN2A, KRAS, BAK1, NFKB1, CCND1, ABL1, BCR, RB1, AKT1, BRAF, MYC
 KEGG 23 / 77 9.1× 1.77e-16 7.44e-14 ✓ sig.
Human T-cell leukemia virus 1 infection
TP53, CDKN2A, KRAS, PTEN, JAK1, CSF2, NFKB1, ATM, CCND1, TCF3, HLA-C, CHEK2
 KEGG 37 / 224 5.0× 2.33e-16 9.56e-14 ✓ sig.
EGFR tyrosine kinase inhibitor resistance
KRAS, PTEN, JAK1, PDGFRA, JAK2, STAT3, AKT1, BRAF, ERBB2, MET, MTOR, IGF1
 KEGG 23 / 80 8.8× 4.53e-16 1.78e-13 ✓ sig.
Central carbon metabolism in cancer
TP53, KRAS, PTEN, FLT3, GLS, PDGFRA, GCK, AKT1, ERBB2, MET, MYC, MTOR
 KEGG 21 / 71 9.0× 4.66e-15 1.54e-12 ✓ sig.
Non-small cell lung cancer
TP53, CDKN2A, KRAS, BAK1, CCND1, RB1, STAT3, AKT1, BRAF, ERBB2, MET, STAT5B
 KEGG 21 / 73 8.8× 8.70e-15 2.69e-12 ✓ sig.
Pancreatic cancer
TP53, CDKN2A, KRAS, JAK1, BAK1, NFKB1, CCND1, RB1, BRCA2, STAT3, AKT1, BRAF
 KEGG 21 / 77 8.3× 2.84e-14 8.10e-12 ✓ sig.
Hepatocellular carcinoma
TP53, APC, CDKN2A, CTNNB1, KRAS, PTEN, BAK1, CCND1, RB1, AKT1, BRAF, MET
 KEGG 30 / 170 5.4× 2.89e-14 8.19e-12 ✓ sig.
Kaposi sarcoma-associated herpesvirus infection
TP53, CTNNB1, KRAS, JAK1, BAK1, CSF2, NFKB1, CCND1, HLA-C, RB1, JAK2, STAT3
 KEGG 32 / 196 5.0× 3.78e-14 1.04e-11 ✓ sig.
Endocrine resistance
TP53, CDKN2A, KRAS, CCND1, RB1, AKT1, BRAF, ERBB2, MTOR, IGF1, HRAS, JUN
 KEGG 23 / 99 7.1× 7.17e-14 1.85e-11 ✓ sig.
MicroRNAs in cancer
TP53, APC, CDKN2A, KRAS, PTEN, BAK1, GLS, NFKB1, ATM, CCND1, FOXP1, PDGFRA
 KEGG 40 / 311 3.9× 8.42e-14 2.16e-11 ✓ sig.
Melanoma
TP53, CDKN2A, KRAS, PTEN, BAK1, CCND1, PDGFRA, RB1, AKT1, BRAF, MET, IGF1
 KEGG 20 / 73 8.4× 1.07e-13 2.71e-11 ✓ sig.
Glioma
TP53, CDKN2A, KRAS, PTEN, BAK1, CCND1, PDGFRA, RB1, AKT1, BRAF, MTOR, IGF1
 KEGG 20 / 76 8.0× 2.49e-13 5.89e-11 ✓ sig.

Enriched GO Terms (Biological Process, a second line of biological evidence)

GO term ⇵ GO ID ⇵ Overlap genes ⇵ Fold enrichment ⇵ P-value ⇵ FDR q-value ⇵
positive regulation of transcription by RNA polymerase II
TP53, CDKN2A, CTNNB1, PTEN, CEBPA, CEBPE, ELK3, ERG, GATA3, IKZF3, IRF1, MYB
 GO:0045944 92 / 1,208 3.6× 4.17e-28 1.87e-24 ✓ sig.
cell population proliferation
TP53, CTNNB1, KRAS, CEBPA, CSF2, GATA3, CCND1, PBX1, RB1, BRCA2, STAT3, AKT1
 GO:0008283 40 / 263 7.2× 5.69e-23 1.40e-19 ✓ sig.
regulation of cell population proliferation
TP53, CTNNB1, CEBPA, CSF2, STAT4, STAT6, PBX1, ABL1, NPM1, MDM4, STAT3, BRAF
 GO:0042127 33 / 201 7.8× 3.48e-20 5.64e-17 ✓ sig.
positive regulation of gene expression
TP53, CDKN2A, CTNNB1, KRAS, CCL2, CEBPA, CEBPE, CSF2, GATA3, IL7, BCL11A, ATM
 GO:0010628 50 / 504 4.7× 4.74e-20 7.42e-17 ✓ sig.
positive regulation of cell population proliferation
CTNNB1, PTEN, CEP43, CSF2, FLT3, IL7, CCND1, PDGFRA, NPM1, JAK2, STAT3, MYC
 GO:0008284 47 / 532 4.2× 7.01e-17 6.78e-14 ✓ sig.
negative regulation of cell population proliferation
SH2B3, TP53, APC, CDKN2A, CTNNB1, PTEN, BAK1, CEBPA, GATA3, IRF1, NPM1, MDM4
 GO:0008285 42 / 444 4.5× 3.15e-16 2.76e-13 ✓ sig.
negative regulation of DNA-templated transcription
TP53, CDKN1C, CDKN2A, CTNNB1, ARID5B, CEBPA, CSF2, ELK3, GATA3, IKZF1, IRF1, MYB
 GO:0045892 50 / 631 3.8× 5.68e-16 4.77e-13 ✓ sig.
negative regulation of transcription by RNA polymerase II
TP53, CDKN1C, CDKN2A, CTNNB1, ARID5B, CEBPA, ELK3, GATA3, MYB, NFKB1, STAT6, BCL11A
 GO:0000122 64 / 1,002 3.0× 1.25e-15 9.76e-13 ✓ sig.
positive regulation of DNA-templated transcription
TP53, CDKN1C, CDKN2A, CTNNB1, ARID5B, CEBPA, GATA3, IRF1, MYB, NFKB1, TCF3, KMT2A
 GO:0045893 55 / 778 3.4× 2.39e-15 1.78e-12 ✓ sig.
negative regulation of apoptotic process
TP53, CTNNB1, HYOU1, IL7, NFKB1, NPM1, MDM4, JAK2, AKR1A1, AKT1, BRAF, ERBB2
 GO:0043066 43 / 524 3.9× 2.19e-14 1.36e-11 ✓ sig.
regulation of cell cycle
TP53, CDKN1C, CDKN2A, PTEN, BAK1, CEBPA, IRF1, ATM, CCND1, ABL1, BCR, NPM1
 GO:0051726 30 / 262 5.4× 4.53e-14 2.67e-11 ✓ sig.
heart development
TP53, CTNNB1, PTEN, TRAF3IP2, ATM, WDR11, ERBB2, PTPRJ, TEK, MDM2, ERBB3, MMP2
 GO:0007507 30 / 273 5.2× 1.36e-13 7.28e-11 ✓ sig.
regulation of gene expression
CDKN2A, CTNNB1, CSF2, IL7, IRF1, MYB, NFKB1, ATM, FOXP1, ABL1, KMT2A, MET
 GO:0010468 36 / 402 4.3× 2.46e-13 1.26e-10 ✓ sig.
neuron differentiation
CTNNB1, GATA3, CCND1, ABL1, RB1, ERBB2, MET, LYPD6, ERBB3, EGFR, HDAC6, RUNX2
 GO:0030182 26 / 222 5.6× 1.38e-12 6.26e-10 ✓ sig.
positive regulation of MAPK cascade
CTNNB1, FLT3, P2RX7, JAK2, ERBB2, PTPRJ, RIT2, SLCO3A1, IGF1, FLT1, HRAS, KDR
 GO:0043410 26 / 224 5.5× 1.71e-12 7.53e-10 ✓ sig.

Pairs within this cluster, by significance

Disease A ⇵ Disease B ⇵ Similarity score ⇵ Shared genes ⇵ P-value ⇵ FDR q-value ⇵
Hemangiosarcoma Uterine neoplasms 0.118 6 2.71e-12 3.11e-11 ✓ sig.
Bone marrow failure syndromes Congenital bone marrow failure syndrome 0.300 3 1.38e-10 1.35e-9 ✓ sig.
Endometrial hyperplasia Nasopharyngeal carcinoma 0.138 4 6.52e-10 6.00e-9 ✓ sig.
B-cell acute lymphoblastic leukemia Lymphoblastic leukemia 0.063 7 2.16e-9 1.88e-8 ✓ sig.
B-lymphoblastic leukemia/lymphoma Lymphoblastic leukemia 0.069 5 6.49e-9 5.42e-8 ✓ sig.
B-cell acute lymphoblastic leukemia B-lymphoblastic leukemia/lymphoma 0.067 5 8.45e-9 6.83e-8 ✓ sig.
Bone osteosarcoma Osteogenic sarcoma 0.500 2 2.53e-8 1.93e-7 ✓ sig.
Bone osteosarcoma Osteosarcoma 0.052 3 4.81e-8 3.58e-7 ✓ sig.
Nasopharyngeal carcinoma Sezary syndrome 0.087 4 5.37e-8 3.92e-7 ✓ sig.
Hemangiosarcoma Urologic neoplasms 0.125 3 7.48e-8 5.40e-7 ✓ sig.
Urogenital neoplasms Vulvar lichen sclerosus 0.333 2 8.44e-8 5.94e-7 ✓ sig.
Uinary system neoplasms Urogenital neoplasms 0.333 2 8.44e-8 5.94e-7 ✓ sig.
Li-fraumeni syndrome Vulvar lichen sclerosus 0.333 2 8.44e-8 5.94e-7 ✓ sig.
Endometrial hyperplasia Hemangiosarcoma 0.115 3 1.60e-7 1.08e-6 ✓ sig.
Nasopharyngeal carcinoma Uterine neoplasms 0.070 4 2.23e-7 1.48e-6 ✓ sig.
Bone osteosarcoma Li-fraumeni syndrome 0.286 2 2.53e-7 1.65e-6 ✓ sig.
Endometrial hyperplasia Vulvar lichen sclerosus 0.182 2 3.80e-7 2.39e-6 ✓ sig.
Sezary syndrome Small cell carcinoma 0.088 3 4.01e-7 2.52e-6 ✓ sig.
Sezary syndrome Small cell lung carcinoma 0.044 5 4.70e-7 2.93e-6 ✓ sig.
Hemangiosarcoma Osteosarcoma 0.056 4 4.97e-7 3.09e-6 ✓ sig.
Endometrial hyperplasia Sezary syndrome 0.086 3 5.72e-7 3.50e-6 ✓ sig.
Li-fraumeni syndrome Urogenital neoplasms 0.222 2 8.43e-7 5.00e-6 ✓ sig.
Li-fraumeni syndrome Sapho syndrome 0.222 2 8.43e-7 5.00e-6 ✓ sig.
Bone osteosarcoma Small cell carcinoma 0.182 2 9.11e-7 5.37e-6 ✓ sig.
B-lymphoblastic leukemia/lymphoma Carcinogenesis 0.086 3 1.28e-6 7.40e-6 ✓ sig.
B-lymphoblastic leukemia/lymphoma Vulvar lichen sclerosus 0.100 2 1.44e-6 8.23e-6 ✓ sig.
Carcinogenesis Nasopharyngeal carcinoma 0.079 3 2.04e-6 1.13e-5 ✓ sig.
Endometrial hyperplasia Li-fraumeni syndrome 0.143 2 3.79e-6 2.01e-5 ✓ sig.
B-cell chronic lymphocytic leukemia Urologic neoplasms 0.133 2 6.60e-6 3.35e-5 ✓ sig.
Demyelinating diseases Osteosarcoma 0.045 3 7.77e-6 3.91e-5 ✓ sig.
B-lymphoblastic leukemia/lymphoma Urogenital neoplasms 0.087 2 1.44e-5 6.95e-5 ✓ sig.
B-lymphoblastic leukemia/lymphoma Li-fraumeni syndrome 0.087 2 1.44e-5 6.95e-5 ✓ sig.
Adrenocortical carcinoma Choroid plexus papilloma 0.500 1 6.49e-5 2.33e-4 ✓ sig.
Choroid plexus carcinoma Choroid plexus papilloma 0.500 1 6.49e-5 2.33e-4 ✓ sig.
Adrenocortical carcinoma Choroid plexus carcinoma 0.500 1 6.49e-5 2.33e-4 ✓ sig.
Carcinogenesis Endometrial hyperplasia 0.074 2 5.78e-5 2.33e-4 ✓ sig.
CHEK2-related cancer predisposition Osteogenic sarcoma 0.333 1 1.30e-4 3.93e-4 ✓ sig.
Adrenocortical carcinoma Central nervous system neoplasms 0.333 1 1.30e-4 3.93e-4 ✓ sig.
Adrenocortical carcinoma Chromosome 17 deletion 0.333 1 1.30e-4 3.93e-4 ✓ sig.
Adrenocortical carcinoma Vulvar lichen sclerosus 0.333 1 1.30e-4 3.93e-4 ✓ sig.
Osteogenic sarcoma Retinoblastoma 0.333 1 1.30e-4 3.93e-4 ✓ sig.
Central nervous system neoplasms Choroid plexus carcinoma 0.333 1 1.30e-4 3.93e-4 ✓ sig.
Choroid plexus carcinoma Chromosome 17 deletion 0.333 1 1.30e-4 3.93e-4 ✓ sig.
Central nervous system neoplasms Choroid plexus papilloma 0.333 1 1.30e-4 3.93e-4 ✓ sig.
Choroid plexus papilloma Vulvar lichen sclerosus 0.333 1 1.30e-4 3.93e-4 ✓ sig.
Choroid plexus papilloma Chromosome 17 deletion 0.333 1 1.30e-4 3.93e-4 ✓ sig.
Choroid plexus carcinoma Vulvar lichen sclerosus 0.333 1 1.30e-4 3.93e-4 ✓ sig.
Bone osteosarcoma Choroid plexus carcinoma 0.250 1 1.95e-4 5.35e-4 ✓ sig.
Bone osteosarcoma Retinoblastoma 0.250 1 1.95e-4 5.35e-4 ✓ sig.
Adrenocortical carcinoma Bone osteosarcoma 0.250 1 1.95e-4 5.35e-4 ✓ sig.
Bone osteosarcoma CHEK2-related cancer predisposition 0.250 1 1.95e-4 5.35e-4 ✓ sig.
Aplasia and myelodysplasia Congenital bone marrow failure syndrome 0.250 1 1.95e-4 5.35e-4 ✓ sig.
Choroid plexus carcinoma Urogenital neoplasms 0.167 1 3.25e-4 7.71e-4 ✓ sig.
CHEK2-related cancer predisposition Li-fraumeni syndrome 0.167 1 3.25e-4 7.71e-4 ✓ sig.
Adrenocortical carcinoma Urogenital neoplasms 0.167 1 3.25e-4 7.71e-4 ✓ sig.
Choroid plexus papilloma Sapho syndrome 0.167 1 3.25e-4 7.71e-4 ✓ sig.
Adrenocortical carcinoma Sapho syndrome 0.167 1 3.25e-4 7.71e-4 ✓ sig.
Choroid plexus carcinoma Sapho syndrome 0.167 1 3.25e-4 7.71e-4 ✓ sig.
Congenital bone marrow failure syndrome Growth hormone insensitivity syndrome with immune dysregulation 0.200 1 3.90e-4 8.67e-4 ✓ sig.
Adrenocortical carcinoma Breast implant-associated anaplastic large cell lymphoma 0.143 1 3.90e-4 8.67e-4 ✓ sig.
Breast implant-associated anaplastic large cell lymphoma Choroid plexus carcinoma 0.143 1 3.90e-4 8.67e-4 ✓ sig.
Breast implant-associated anaplastic large cell lymphoma Choroid plexus papilloma 0.143 1 3.90e-4 8.67e-4 ✓ sig.
Autoinflammation, immune dysregulation, and eosinophilia Breast implant-associated anaplastic large cell lymphoma 0.143 1 3.90e-4 8.67e-4 ✓ sig.
Familial telangiectasia cancer syndrome Urologic neoplasms 0.111 1 5.20e-4 1.06e-3 ✓ sig.
Adrenocortical carcinoma B-cell chronic lymphocytic leukemia 0.111 1 5.20e-4 1.06e-3 ✓ sig.
B-cell chronic lymphocytic leukemia Choroid plexus papilloma 0.111 1 5.20e-4 1.06e-3 ✓ sig.
B-cell chronic lymphocytic leukemia Choroid plexus carcinoma 0.111 1 5.20e-4 1.06e-3 ✓ sig.
Adrenocortical carcinoma Urologic neoplasms 0.111 1 5.20e-4 1.06e-3 ✓ sig.
Choroid plexus carcinoma Urologic neoplasms 0.111 1 5.20e-4 1.06e-3 ✓ sig.
Choroid plexus papilloma Urologic neoplasms 0.111 1 5.20e-4 1.06e-3 ✓ sig.
Choroid plexus papilloma Small cell carcinoma 0.100 1 5.84e-4 1.16e-3 ✓ sig.
Choroid plexus carcinoma Small cell carcinoma 0.100 1 5.84e-4 1.16e-3 ✓ sig.
Adrenocortical carcinoma Small cell carcinoma 0.100 1 5.84e-4 1.16e-3 ✓ sig.
Aplasia and myelodysplasia Bone marrow failure syndromes 0.100 1 5.84e-4 1.16e-3 ✓ sig.
Bone marrow failure syndromes Congenital progressive bone marrow failure-b-cell immunodeficiency-skeletal dysplasia syndrome 0.100 1 5.84e-4 1.16e-3 ✓ sig.
Adrenocortical carcinoma Bone marrow failure syndromes 0.100 1 5.84e-4 1.16e-3 ✓ sig.
Bone marrow failure syndromes Choroid plexus carcinoma 0.100 1 5.84e-4 1.16e-3 ✓ sig.
Retinoblastoma Small cell carcinoma 0.100 1 5.84e-4 1.16e-3 ✓ sig.
Bone marrow failure syndromes Choroid plexus papilloma 0.100 1 5.84e-4 1.16e-3 ✓ sig.
Demyelinating diseases Merkel cell carcinoma 0.083 1 7.14e-4 1.34e-3 ✓ sig.
Adrenocortical carcinoma Demyelinating diseases 0.083 1 7.14e-4 1.34e-3 ✓ sig.
Choroid plexus carcinoma Demyelinating diseases 0.083 1 7.14e-4 1.34e-3 ✓ sig.
Choroid plexus papilloma Demyelinating diseases 0.083 1 7.14e-4 1.34e-3 ✓ sig.
Bone marrow failure syndromes Growth hormone insensitivity syndrome with immune dysregulation 0.091 1 1.17e-3 1.90e-3 ✓ sig.
Hemangiosarcoma Merkel cell carcinoma 0.053 1 1.17e-3 1.90e-3 ✓ sig.
Hemangiosarcoma immune dysregulation, autoimmunity, and autoinflammation 0.053 1 1.17e-3 1.90e-3 ✓ sig.
Carcinogenesis Gestational trophoblastic disease 0.053 1 1.17e-3 1.90e-3 ✓ sig.
B-lymphoblastic leukemia/lymphoma leukemia, acute myeloid, susceptibility to 0.050 1 1.23e-3 1.99e-3 ✓ sig.
Cervicitis Sezary syndrome 0.036 1 1.75e-3 2.61e-3 ✓ sig.
Sezary syndrome snijders blok-campeau syndrome 0.036 1 1.75e-3 2.61e-3 ✓ sig.
immune dysregulation, autoimmunity, and autoinflammation Sezary syndrome 0.036 1 1.75e-3 2.61e-3 ✓ sig.
B-cell acute lymphoblastic leukemia granulocytopenia with immunoglobulin abnormality 0.016 1 3.90e-3 4.94e-3 ✓ sig.
Nasopalpebral lipoma-coloboma syndrome Small cell lung carcinoma 0.011 1 5.91e-3 7.12e-3 ✓ sig.